TI
NKTR icon

Trexquant Investment’s Nektar Therapeutics NKTR Stock Holding History

Trexquant Investment’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.99M Buy
55,476
+36,655
+195% +$2.09M 0.03% 747
2025
Q4 		$796K Sell
18,821
-72,659
-79% -$4.07M 0.01% 1250
2025
Q3 		$5.21M Buy
+91,480
New +$3.03M 0.05% 539
2020
Q4 		– Sell
-2,388
Closed -$594K – 1344
2020
Q3 		$594K Sell
2,388
-1,543
-39% -$485K 0.04% 614
2020
Q2 		$1.37M Sell
3,931
-646
-14% -$202K 0.09% 300
2020
Q1 		$1.23M Buy
4,577
+2,715
+146% +$840K 0.09% 346
2019
Q4 		$603K Buy
+1,862
New +$540K 0.04% 504
2018
Q4 		– Sell
-4,623
Closed -$4.23M – 1220
2018
Q3 		$4.23M Sell
4,623
-371
-7% -$317K 0.32% 87
2018
Q2 		$3.66M Buy
4,994
+4,759
+2,025% +$5.49M 0.25% 126
2018
Q1 		$374K Buy
+235
New +$303K 0.03% 728
2017
Q2 		– Sell
-3,806
Closed -$1.34M – 1054
2017
Q1 		$1.34M Buy
3,806
+170
+5% +$38.2K 0.17% 152
2016
Q4 		$669K Buy
3,636
+2,095
+136% +$426K 0.11% 322
2016
Q3 		$397K Sell
1,541
-110
-7% -$28.3K 0.09% 371
2016
Q2 		$352K Buy
+1,651
New +$369K 0.05% 605
2016
Q1 		– Sell
-1,160
Closed -$293K – 1087
2015
Q4 		$293K Sell
1,160
-215
-16% -$44.2K 0.03% 856
2015
Q3 		$226K Sell
1,375
-278
-17% -$49.2K 0.02% 941
2015
Q2 		$310K Sell
1,653
-4,107
-71% -$707K 0.03% 804
2015
Q1 		$950K Buy
5,760
+4,147
+257% +$852K 0.1% 392
2014
Q4 		$375K Buy
+1,613
New +$345K 0.07% 589

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Trexquant Investment's NKTR Position: Q1 2026 in Review

Trexquant Investment increased its Nektar Therapeutics (NKTR) stake by 195% in Q1 2026, buying an estimated $2.09M and bringing the position to 55,476 shares worth $3.99M. The position accounts for 0.03% of the portfolio, ranked #747.

Trexquant Investment first reported a position in NKTR in Q4 2014 and has held it in 19 quarters since. The position peaked at $5.21M in Q3 2025. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Trexquant Investment held 55,476 shares of Nektar Therapeutics worth $3.99M as of Q1 2026.
  • Trexquant Investment bought 36,655 Nektar Therapeutics shares in Q1 2026, an estimated $2.09M.
  • Nektar Therapeutics made up 0.03% of Trexquant Investment's portfolio in Q1 2026, its #747 holding.
  • Trexquant Investment first reported a position in Nektar Therapeutics in Q4 2014 and has held it in 19 quarters since.
  • Trexquant Investment's Nektar Therapeutics position peaked at $5.21M in Q3 2025.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.